Dimerix Licenses DMX200 to Everest for China and Asia Region
Filed with ASX · · 4 pages · English
Story so far
Earlier from Dimerix
- Dimerix Quarterly Activities Report and Appendix 4C
- Blinded assessment of ACTION3 statistical assumptions complete
- ACTION3 Statistical Review Complete
- Dimerix to Conduct Review of ACTION3 Statistical Assumptions
- Dimerix Phase 3 Trial Last Patient Receives First Dose
Later from Dimerix
- Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines
- DMX-200 Available To Patients Via Post-Trial Access Pathways
- Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
- Dimerix Expands Pipeline with Acquisition of Phase 2 Asset
- Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix